Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 3/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20813785 | 0.76 | PARP1 (0.44) | MAP4K4PARP1ACHE | |
| SCHEMBL3276096 | 0.76 | PDE4A (0.48) | PARP1 | |
| SCHEMBL29461096 | 0.76 | PDE4A (0.48) | PARP1 | |
| SCHEMBL14521105 | 0.76 | PARP1 (0.44) | PARP1ACHE | |
| SCHEMBL8664052 | 0.76 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL18312022 | 0.76 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL17227469 | 0.76 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL18312242 | 0.76 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| Hydrochloric Acid SCHEMBL4029810 | 0.74 | PDE4A (0.47) | PARP1 | |
| SCHEMBL23885475 | 0.74 | LIMK1 (0.39) | PI4KAPI4K2BPI4K2API4KBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-3448839-B1 | QUINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORP (KR) | 2022-02-09 | — | — | EP | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| WO-2018134148-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6696482-B2 | QUINAZOLINE, NITROTHIAZOLE AND INDOLINONE BASED HYDROPHOBIC FORMULATIONS FOR ORAL ADMINISTRATION FOR TREATING CELL PROLIFERATION DISORDER IN A MAMMAL | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | disclosed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-1014953-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | Sugen, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998038984-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | PI4KA 906/4885PI4K2B 2095/4885PI4K2A 1483/4885 |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | PI4KA 152/4885PI4K2B 176/4885PI4K2A 137/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PI4KA 4129/4885PI4K2B 3485/4885PI4K2A 3846/4885 |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | PI4KA 151/4885PI4K2B 171/4885PI4K2A 149/4885 |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | PI4KA 552/4885PI4K2B 655/4885PI4K2A 583/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | PI4KA 151/4885PI4K2B 171/4885PI4K2A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.